prx002
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2014 (NCT02095171)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Alpha-synucleinINHIBITOR
SNCA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- prx002
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02157714 | Phase 1 | Jun 1, 2014 | Prothena Biosciences Inc, Roche |
| NCT02095171 | Phase 1 | Mar 1, 2014 | Prothena Biosciences Inc, Roche |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Prothena Biosciences Inc | For profit | 2 | 2 | 1 | 2014 |
| Roche | For profit | 2 | 0 | 1 | 2014 |
2 organizations
Page 1 / 1